Undisclosed (Cardiometabolic)
Cardiometabolic Disease
Phase 1Active
Key Facts
About SanegeneBio
SanegeneBio is a private, global biotech leveraging its proprietary LEAD™ technology to develop RNAi therapies targeting obesity, cardiometabolic, and autoimmune diseases. The company has advanced multiple programs into clinical trials, supported by over $150 million in funding, and operates R&D centers in both the US and China. Its strategy centers on expanding RNAi beyond liver targets to address large patient populations with chronic conditions through tissue-specific delivery and optimized payloads.
View full company profileTherapeutic Areas
Other Cardiometabolic Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| PCSK9 Program | nChroma Bio | Candidate-Enabled |
| PCSK9 Multiplex Program | nChroma Bio | Research |
| Undisclosed Peripheral | Manifold Bio | Pre-clinical |